News Releases

Date Title and Summary View
October 4, 2022
- Safety signals observed will not yield targeted product profile – - No impact on Sebetralstat expected safety profile or Phase 3 KONFIDENT trial – - Oral Factor XIIa program to become primary focus for HAE prophylaxis - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Oct....
Additional Formats
September 30, 2022
- Data provides patient perspectives on optimal treatment outcomes and quality-of-life challenges for people living with HAE - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 30, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on...
Additional Formats
September 8, 2022
- KVD824 Phase 2 Clinical Trial Reaches 50% Enrollment Milestone – - Open Label Extension Study Initiated for Sebetralstat – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 8, 2022-- KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the...
Additional Formats
September 2, 2022
CAMBRIDGE, Mass & SALISBURY, England --(BUSINESS WIRE)--Sep. 2, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 18,000 shares of...
Additional Formats
August 23, 2022
- NDA-supporting study extension provides additional two years of treatment with sebetralstat to assess long-term safety and tolerability in HAE patients - - Subtrial will assess sebetralstat profile in adolescent patients - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Aug....
Additional Formats
August 2, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Aug. 2, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 7,000 shares of...
Additional Formats
July 19, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul. 19, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be...
Additional Formats
July 7, 2022
– Sebetralstat Phase 3 KONFIDENT and KVD824 Phase 2 KOMPLETE Clinical Trial Enrollment on Track – – Formal Notification Received of Sebetralstat EU Orphan Drug Status – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul. 7, 2022-- KalVista Pharmaceuticals, Inc....
Additional Formats
July 5, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul. 5, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 8,000 shares of...
Additional Formats
July 5, 2022
– Sebetralstat data examines efficacy by attack location and population PK comparisons – – Preclinical data for oral Factor XIIa inhibitor shows durable suppression of kallikrein-kinin system - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul. 5, 2022-- KalVista Pharmaceuticals, Inc....
Additional Formats
Displaying 1 - 10 of 28